A Systematic Review of Companion Diagnostic Tests by Immunohistochemistry for the Screening of Alectinib-Treated Patients in ALK-Positive Non-Small Cell Lung Cancer

A Systematic Review of Companion Diagnostic Tests by Immunohistochemistry for the Screening of Alectinib-Treated Patients in ALK-Positive Non-Small Cell Lung Cancer

Companion diagnostic tests and targeted therapy changed the management of non-small cell lung cancer by diagnosing genetic modifications and enabling individualized treatment. The purpose of this systematic review is to assess the clinical applicability of companion diagnostic tests (IHC method) by...

Full description

Bibliographic Details
Main Authors:	Sulim Kang, Jaehyun Woo, Sungmin Kim
Format:	Article
Language:	English
Published:	MDPI AG 2022-05-01
Series:	Diagnostics
Subjects:	companion diagnostic test immunohistochemistry alectinib ALK non-small cell lung cancer
Online Access:	https://www.mdpi.com/2075-4418/12/5/1297

Similar Items

Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib
by: Justin M. Cheung, MD, et al.
Published: (2024-03-01)

Concomitant double-fusion of PLEKHA7-ALK and INPP5D-ALK reveals favorable alectinib sensitivity in lung adenocarcinoma: a case report and literature review
by: Pei Li, et al.
Published: (2024-02-01)

Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study
by: Caicun Zhou, MD, PhD, et al.
Published: (2024-09-01)

Analysis of Baseline Molecular Factors Associated With the Risk of Central Nervous System Progression Among Alectinib-Treated Patients With ALK–Positive NSCLC
by: Lianxi Song, MD, et al.
Published: (2024-12-01)

Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence
by: Yurong Wang, et al.
Published: (2022-12-01)

Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports
by: Liang Shi, et al.
Published: (2023-06-01)

Novel PPFIA1-ALK, ALK-C2orf91(intergenic) double-fusion responded well to alectinib in an advanced lung adenocarcinoma patient: a case report
by: Lingxin Yan, et al.
Published: (2023-08-01)

CLINICAL EFFICACY OF TARGETED THERAPY TOWARDS METASTATIC LUNG CANCER CARRYING DISTINCT TYPES OF ALK REARRANGEMENTS
by: N. V. Mitiushkina, et al.
Published: (2020-09-01)

Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review
by: Hongxia Wang, et al.
Published: (2025-01-01)

Coexistence of a novel SV2B-ALK, EML4-ALK double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review
by: Huang Chen, et al.
Published: (2024-12-01)

Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
by: Gianluca Spitaleri, et al.
Published: (2023-05-01)

Lorlatinib overcomes alectinib‐induced hemolytic anemia in an ALK fusion positive non‐small‐cell lung cancer patient with severe tumor‐associated liver failure: A case report
by: Kei Kunimasa, et al.
Published: (2024-12-01)

Alectinib and lorlatinib function by modulating EMT-related proteins and MMPs in NSCLC metastasis
by: Xu Feng, et al.
Published: (2021-06-01)

Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada
by: Lara Chayab, et al.
Published: (2024-12-01)

Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review
by: Qin Chen, et al.
Published: (2023-11-01)

Successful Treatment of ALK-Positive Large-Cell Neuroendocrine Carcinoma of the Lung With Sequential ALK Inhibitors: A Case Report
by: Takayuki Kobayashi, MD, et al.
Published: (2023-07-01)

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis
by: Ibiayi Dagogo-Jack, MD, et al.
Published: (2023-08-01)

Spontaneous Bilateral Chylothorax Development During Alectinib Therapy for ALK-Rearranged NSCLC—A Case Report
by: Sunanjay Bajaj, MD, et al.
Published: (2023-12-01)

Is Elevation of Alkaline Phosphatase a Predictive Factor of Response to Alectinib in NSCLC?
by: Walid Shalata, et al.
Published: (2021-12-01)

Partial response to treatment with ALK inhibitor in a patient with SQSTM1-ALK fusion positive lung adenocarcinoma
by: Brenda Paola Rodriguez Arroyo, et al.
Published: (2024-11-01)

Acquired L1196M ALK mutation in anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma during alectinib administration
by: Kazuhiro Noguchi, et al.
Published: (2023-02-01)

Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion
by: Cesare Gridelli, et al.
Published: (2023-11-01)

The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic review and sensitivity-analysis
by: Luca Mastrantoni, et al.
Published: (2024-01-01)

Evaluation of ALK, EGFR and PD-L1 Mutations in Pulmonary Carcinomas through Immunohistochemistry
by: Teona Bushati, et al.
Published: (2023-07-01)

New Perspectives in the Treatment of Inflammatory Myofibroblastic Tumor with ALK Translocation: Case Report
by: Johana Benedetti Pedroza, et al.
Published: (2024-07-01)

Successful treatment of a non‐small‐cell lung cancer patient harboring HIP1‐ALK (H28:A20) and CTNNB1 p.S45del with alectinib
by: Vito Longo, et al.
Published: (2024-11-01)

First case report of a novel KIF13A-ALK fusion in a lung adenocarcinoma patient and response to alectinib with a 4-year follow-up
by: Zheng Mo, et al.
Published: (2023-12-01)

Modern treatment of ALK-positive non-small cell lung cancer
by: D. A. Kharagezov, et al.
Published: (2022-06-01)

ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia
by: Lee AT, et al.
Published: (2023-07-01)

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
by: Valerio Gristina, et al.
Published: (2020-12-01)

Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study
by: A. S. Kolbin, et al.
Published: (2023-11-01)

Future Perspective for ALK-Positive Anaplastic Large Cell Lymphoma with Initial Central Nervous System (CNS) Involvement: Could Next-Generation ALK Inhibitors Replace Brain Radiotherapy for the Prevention of Further CNS Relapse?
by: Makito Tanaka, et al.
Published: (2023-05-01)

Pneumothorax during Alectinib Treatment for a Uterine Inflammatory Myofibroblastic Tumor with Lung Metastasis
by: Chang-Ting Lin, et al.
Published: (2023-04-01)

Safety of brigatinib following alectinib-induced-pneumonitis: Case report
by: Blerina Resuli, et al.
Published: (2025-01-01)

Lorlatinib After Alectinib-Induced Pneumonitis: A Case Report
by: James A. Fletcher, M.B.B.S., et al.
Published: (2024-02-01)

Photophysical Exploration of Alectinib and Rilpivirine: Insights from Theory and Experiment
by: Chun Zhang, et al.
Published: (2023-08-01)

Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK‐positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib
by: Yuki Sato, et al.
Published: (2024-08-01)

A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib
by: Chloe A. Lim, et al.
Published: (2022-02-01)

A case of inflammatory myofibroblastic tumor harboring EML4‐ALK fusion with a brain metastasis responding to alectinib
by: Soichiro Sakoda, et al.
Published: (2024-02-01)

Correlation between ALK, ROS1 Biomarkers and EGFR Oncogene Mutations in Lung Tumours: Our Observations in an Apex Oncopathology Laboratory
by: Raja Ratna Kishore, et al.
Published: (2023-05-01)